Regent Investment Management LLC reduced its stake in ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 9.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,009 shares of the specialty pharmaceutical company’s stock after selling 4,030 shares during the period. ANI Pharmaceuticals makes up about 1.0% of Regent Investment Management LLC’s investment portfolio, making the stock its 26th biggest holding. Regent Investment Management LLC owned approximately 0.32% of ANI Pharmaceuticals worth $3,207,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Financial Gravity Wealth Inc. bought a new stake in ANI Pharmaceuticals during the first quarter worth approximately $54,000. Quantamental Technologies LLC raised its stake in ANI Pharmaceuticals by 169.4% in the 1st quarter. Quantamental Technologies LLC now owns 862 shares of the specialty pharmaceutical company’s stock valued at $61,000 after acquiring an additional 542 shares during the period. Municipal Employees Retirement System of Michigan bought a new stake in ANI Pharmaceuticals in the 4th quarter valued at about $115,000. BNP Paribas Arbitrage SA raised its stake in ANI Pharmaceuticals by 55,466.7% in the 1st quarter. BNP Paribas Arbitrage SA now owns 1,667 shares of the specialty pharmaceutical company’s stock valued at $118,000 after acquiring an additional 1,664 shares during the period. Finally, Metropolitan Life Insurance Co. NY raised its stake in ANI Pharmaceuticals by 324.2% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 2,872 shares of the specialty pharmaceutical company’s stock valued at $129,000 after acquiring an additional 2,195 shares during the period. Hedge funds and other institutional investors own 64.04% of the company’s stock.

Shares of NASDAQ:ANIP traded up $0.13 on Monday, hitting $84.39. 4,522 shares of the company were exchanged, compared to its average volume of 124,544. The firm’s 50 day moving average price is $78.56. ANI Pharmaceuticals Inc has a one year low of $36.92 and a one year high of $85.15. The company has a debt-to-equity ratio of 0.33, a current ratio of 0.92 and a quick ratio of 0.67. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of 18.38 and a beta of 2.25.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Thursday, May 9th. The specialty pharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.25. ANI Pharmaceuticals had a return on equity of 28.63% and a net margin of 6.58%. The business had revenue of $52.90 million during the quarter, compared to the consensus estimate of $50.57 million. During the same quarter in the prior year, the company earned $1.32 earnings per share. The firm’s quarterly revenue was up 13.8% compared to the same quarter last year. As a group, equities analysts expect that ANI Pharmaceuticals Inc will post 5.57 EPS for the current year.

In other ANI Pharmaceuticals news, insider Arthur Przybyl sold 30,000 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $70.07, for a total transaction of $2,102,100.00. Following the completion of the sale, the insider now directly owns 222,994 shares of the company’s stock, valued at approximately $15,625,189.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David Nash purchased 1,445 shares of the firm’s stock in a transaction on Friday, May 24th. The shares were acquired at an average cost of $68.76 per share, with a total value of $99,358.20. Following the completion of the acquisition, the director now directly owns 5,236 shares in the company, valued at $360,027.36. The disclosure for this purchase can be found here. Insiders have sold a total of 50,911 shares of company stock valued at $3,585,114 over the last ninety days. 24.70% of the stock is owned by company insiders.

Several research analysts have issued reports on ANIP shares. Raymond James reissued a “buy” rating on shares of Canadian Natural Resources in a research report on Friday, May 10th. Cantor Fitzgerald reissued a “buy” rating and set a $27.00 price target on shares of Spero Therapeutics in a research note on Thursday, May 9th. BidaskClub lowered Woodward, Inc.Common Stock from a “strong-buy” rating to a “buy” rating in a research note on Saturday. ValuEngine raised Xylem from a “hold” rating to a “buy” rating in a research note on Friday, June 21st. Finally, Canaccord Genuity lowered Magellan Aerospace from a “buy” rating to a “hold” rating and decreased their price target for the stock from C$21.00 to C$20.00 in a research note on Monday, May 13th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. ANI Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $88.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Featured Article: Overbought

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals Inc (NASDAQ:ANIP).

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.